Hospira Says Its $70M Loss Makes IP Safe Harbor 'Illusory'
The Federal Circuit's decision to uphold a $70 million infringement verdict against Hospira Inc. tied to its biosimilar version of Amgen Inc.'s Epogen "calls into question the continuing viability" of a...To view the full article, register now.
Already a subscriber? Click here to view full article